CAPTRUST Financial Advisors
ACAD icon

CAPTRUST Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+7,951
New +$175K ﹤0.01% 2885
2026
Q1 		– Sell
-8,245
Closed -$220K – 3017
2025
Q4 		$220K Buy
+8,245
New +$197K ﹤0.01% 2460
2024
Q1 		– Sell
-44,164
Closed -$1.38M – 2140
2023
Q4 		$1.38M Sell
44,164
-21,290
-33% -$508K ﹤0.01% 1085
2023
Q3 		$1.36M Buy
65,454
+1,685
+3% +$45.8K 0.01% 1024
2023
Q2 		$1.53M Buy
+63,769
New +$1.42M 0.01% 949
2022
Q3 		– Sell
-1,051
Closed -$15K – 2071
2022
Q2 		$15K Sell
1,051
-1,133
-52% -$21.1K ﹤0.01% 3519
2022
Q1 		$53K Buy
2,184
+103
+5% +$2.49K ﹤0.01% 2739
2021
Q4 		$49K Buy
2,081
+1,268
+156% +$25.5K ﹤0.01% 2682
2021
Q3 		$14K Sell
813
-1,381
-63% -$26.6K ﹤0.01% 3387
2021
Q2 		$54K Sell
2,194
-349
-14% -$7.88K ﹤0.01% 2463
2021
Q1 		$66K Buy
2,543
+758
+42% +$33.4K ﹤0.01% 2240
2020
Q4 		$95K Buy
+1,785
New +$88.6K ﹤0.01% 1525
2020
Q3 		– Sell
-150
Closed -$8K – 3034
2020
Q2 		$8K Buy
+150
New +$7.2K ﹤0.01% 2244
2019
Q3 		– Sell
-350
Closed -$9K – 1920
2019
Q2 		$9K Hold
350
– – ﹤0.01% 1517
2019
Q1 		$9K Hold
350
– – ﹤0.01% 1402
2018
Q4 		$6K Sell
350
-367
-51% -$7.13K ﹤0.01% 1300
2018
Q3 		$15K Sell
717
-298
-29% -$4.69K ﹤0.01% 1097
2018
Q2 		$15K Buy
1,015
+565
+126% +$10.1K ﹤0.01% 1038
2018
Q1 		$9K Sell
450
-100
-18% -$2.77K ﹤0.01% 1041
2017
Q4 		$17K Buy
550
+200
+57% +$6.4K ﹤0.01% 833
2017
Q3 		$10K Buy
+350
New +$11.4K ﹤0.01% 432

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAPTRUST Financial Advisors's ACAD Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 7,951 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #2885 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in ACAD as recently as Q4 2025.

CAPTRUST Financial Advisors first reported a position in ACAD in Q3 2017 and has held it in 21 quarters since. The position peaked at $1.53M in Q2 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • CAPTRUST Financial Advisors held 7,951 shares of Acadia Pharmaceuticals worth $201K as of Q2 2026.
  • Acadia Pharmaceuticals was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2885 holding.
  • CAPTRUST Financial Advisors first reported a position in Acadia Pharmaceuticals in Q3 2017 and has held it in 21 quarters since.
  • CAPTRUST Financial Advisors's Acadia Pharmaceuticals position peaked at $1.53M in Q2 2023.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.